Sep 29, 2014
Hemispherx Biopharma Expands Research on Potential Ebola Treatments to Five Independent Experts/Institutional Collaborators
Sep 22, 2014
Hemispherx Announces Primate Research Showing Alferon® LDO Protection from Pulmonary Damage Associated with Infection by Highly Pathogenic Influenza Virus
Sep 15, 2014
Hemispherx' Drug Ampligen Plus Intranasal Seasonal Influenza Vaccine Induces Cross-Reactive Antibody Formation Against Avian H5N1 and H7N9 Influenza HA in Humans
Sep 10, 2014
Hemispherx Biopharma and the Swiss Department of Defense, Civil Protection and Sports Expand Their Collaborative Research Agreement to Include the Study of Alferon® and Ampligen® Against the Ebola Virus
Sep 08, 2014
Hemispherx Biopharma and United States Army Medical Research Institute of Infectious Diseases (USAMRIID) Agree to Collaborate in Studying Alferon® and Ampligen® Against the Ebola Virus
Sep 03, 2014
HEMISPHERX BIOPHARMA TO PRESENT AT THE 16TH ANNUAL RODMAN & RENSHAW GLOBAL INVESTMENT CONFERENCE IN NEW YORK CITY SEPTEMBER 8-10TH
Aug 11, 2014
HEMISPHERX BIOPHARMA ANNOUNCES FINANCIAL RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2014
Aug 04, 2014
Hemispherx's Two Drugs, Ampligen® and Alferon® Ranked Highly in Sensitivity Testing Against MERS/SARS Coronaviruses
Jul 22, 2014
Hemispherx Achieves High Ranking in Sensitivity Testing Against MERS/SARS Coronaviruses Compared to Other Drugs
Jul 14, 2014
Hemispherx Biopharma and Bioclones, A Leading South African Biotechnology Company, Join Forces on Novel Therapeutic Cancer Vaccine
 1     2    3   4   5 
 <<   <   >   >>